| Thomas R Biehl, MD | |
|
1100 9th Ave, Seattle, WA 98101-2756 | |
| (206) 223-6600 | |
| (206) 515-5886 |
| Full Name | Thomas R Biehl |
|---|---|
| Gender | Male |
| Speciality | General Surgery |
| Experience | 37 Years |
| Location | 1100 9th Ave, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023084761 | NPI | - | NPPES |
| 020038843 | Other | WA | RAILROAD MEDICARE |
| 0039588 | Other | WA | L&I |
| MD9827 | Medicaid | AK | |
| BI0297 | Other | WA | INDIVIDUAL BLUE SHIELD |
| 8211062 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | MD00027098 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virginia Mason Medical Center | Seattle, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virginia Mason Medical Center | 9830002617 | 825 |
News Archive
Tipping back one too many cocktails during an individual's early 20s doesn't correlate to a personal sense of immaturity; however if this habit doesn't stop as they reach age 30, young adults can feel psychologically underdeveloped, according to a University of Missouri study. Helping young adults acknowledge their mental impulse to "sober up" as they mature can improve substance abuse intervention programs.
Researchers at The Saban Research Institute of Children's Hospital Los Angeles have identified a new genetic candidate for testing therapies that might affect fear learning in people with PTSD or other conditions. Results of the study have been published in the Journal of Neuroscience.
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
› Verified 2 days ago
| Entity Name | Virginia Mason Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801851258 PECOS PAC ID: 9830002617 Enrollment ID: O20031107000383 |
News Archive
Tipping back one too many cocktails during an individual's early 20s doesn't correlate to a personal sense of immaturity; however if this habit doesn't stop as they reach age 30, young adults can feel psychologically underdeveloped, according to a University of Missouri study. Helping young adults acknowledge their mental impulse to "sober up" as they mature can improve substance abuse intervention programs.
Researchers at The Saban Research Institute of Children's Hospital Los Angeles have identified a new genetic candidate for testing therapies that might affect fear learning in people with PTSD or other conditions. Results of the study have been published in the Journal of Neuroscience.
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Thomas R Biehl, MD 1100 Olive Way, Ms: M4-pa, Seattle, WA 98101-1873 Ph: (206) 515-5811 | Thomas R Biehl, MD 1100 9th Ave, Seattle, WA 98101-2756 Ph: (206) 223-6600 |
News Archive
Tipping back one too many cocktails during an individual's early 20s doesn't correlate to a personal sense of immaturity; however if this habit doesn't stop as they reach age 30, young adults can feel psychologically underdeveloped, according to a University of Missouri study. Helping young adults acknowledge their mental impulse to "sober up" as they mature can improve substance abuse intervention programs.
Researchers at The Saban Research Institute of Children's Hospital Los Angeles have identified a new genetic candidate for testing therapies that might affect fear learning in people with PTSD or other conditions. Results of the study have been published in the Journal of Neuroscience.
Eleven Biotherapeutics, a biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, announced today the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $10.00 per share, before underwriting discounts and commissions.
Clinical Data, Inc., today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vilazodone for the treatment of major depressive disorder (MDD). Vilazodone is a dual-acting potent and selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist. The Company expects that the NDA submission, if accepted, will be subject to a standard review.
› Verified 2 days ago
Dr. Matthew Alexander Johnston, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1221 E Madison St, Ste 1401, Seattle, WA 98122 Phone: 206-386-6702 | |
Dr. Emily Norpell Palmquist, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Megan Judith Lenihan, MD Surgery Medicare: Medicare Enrolled Practice Location: 747 Broadway, Heath Building, Suite 1003, Seattle, WA 98122 Phone: 201-835-5911 | |
Michael Russell, Surgery Medicare: Medicare Enrolled Practice Location: 747 Broadway Heath Building 10th Floor, Seattle, WA 98122 Phone: 206-251-4253 | |
Robert Dale Mcclure, MD Surgery Medicare: Not Enrolled in Medicare Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-223-6600 | |
Abigail K Wiebusch, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1100 9th Ave, Seattle, WA 98101 Phone: 206-341-0060 |